William Blair & Company, LLC.
William Blair & Company, LLC.
Exhibit 1
ARIAD Pharmaceuticals, Inc.
Sum-of-Parts Fair Value
(dollars in thousands)
Drug Peak Sales Stage of
Development Estimated
Launch Date Probability of
Commercialization Percentage of
Sales to Company Probability.
Adjusted NPV Value
per Share Percentage of
Fair Value
Iclusig-CML 9746.822 Marketed January 2013/ 100% 100% $1,843,975 $9.85 83.4% Worldwide July 2013
AP28113—ALK* NSCLC S280918 Phase Ifl I 1-12 2016 81% 100% $325,268 $1.74 14.7% Worldwide
Subtotal $2,189,243 $11.59 98.2%
Net Cash at Yearend 2014 $63,406 $0.34 2.9%
Net Present Value of additional Gain (Loss)' ($22,727) ($0.12) (1.0%)
Sum-of-Parts Fair Value $2,209,922 $11.81 100.0%
- Includes costs nal *Golly reined to programs above
Sources. Company reports and %ma'am Emir 8 Company. L L.C. estimates
5 I Y. Katherine Xu, Ph.D.
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e)
CONFIDENTIAL DB-SDNY-0 106554
SDNY_GM_00252738
EFTA01450729